Financials data is unavailable for this security.
View more
Year on year Daito Pharmaceutical Co Ltd had net income fall -8.47% from 3.60bn to 3.29bn despite a 3.98% increase in revenues from 45.10bn to 46.90bn. An increase in the cost of goods sold as a percentage of sales from 77.09% to 79.02% was a component in the falling net income despite rising revenues.
| Gross margin | 20.98% |
|---|---|
| Net profit margin | 6.78% |
| Operating margin | 8.24% |
| Return on assets | 4.29% |
|---|---|
| Return on equity | 6.41% |
| Return on investment | 5.58% |
More ▼
Cash flow in JPYView more
In 2024, cash reserves at Daito Pharmaceutical Co Ltd fell by 880.00m. However, the company earned 5.18bn from its operations for a Cash Flow Margin of 11.05%. In addition the company used 5.93bn on investing activities and also paid 183.00m in financing cash flows.
| Cash flow per share | 435.73 |
|---|---|
| Price/Cash flow per share | 5.00 |
| Book value per share | 3,404.72 |
|---|---|
| Tangible book value per share | 3,372.68 |
More ▼
Balance sheet in JPYView more
| Current ratio | 2.24 |
|---|---|
| Quick ratio | 1.11 |
| Total debt/total equity | 0.1675 |
|---|---|
| Total debt/total capital | 0.143 |
More ▼
Growth rates in JPY
SmartText is unavailable
| Div yield(5 year avg) | 1.91% |
|---|---|
| Div growth rate (5 year) | 11.67% |
| Payout ratio (TTM) | 28.38% |
| EPS growth(5 years) | -3.83 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -7.60 |
More ▼
